Capvaxive is on the NIP: who's now eligible for a free pneumo vaccine

What just happened

A new pneumococcal vaccine has been listed on Australia’s National Immunisation Program (NIP), effective 1 July 2026 — and with it comes the largest expansion of adult pneumococcal vaccine eligibility in years.

Capvaxive (21vPCV) is a 21-valent pneumococcal conjugate vaccine, registered for adults aged 18 and over. Its listing on the NIP also comes with two significant changes to who qualifies for a free vaccination:

• The general adult eligibility age has dropped from 70 to 65 years.
• The eligible age for Aboriginal and Torres Strait Islander adults has dropped from 50 to 25 years.
• Adults aged 18+ with specific chronic conditions — including COPD and chronic liver disease — are newly eligible regardless of age.

In addition, Pneumovax 23 (the 23-valent polysaccharide vaccine, 23vPPV) has been removed from the standard recommended schedule. The Australian Immunisation Handbook now states that “the extra benefit of 23vPPV is considered minimal when 20vPCV or 21vPCV is used.”

More than 1.8 million Australians who were not previously eligible for a free pneumococcal vaccine now are.

---

The both-and

Why are conjugate vaccines replacing polysaccharide vaccines?

Pneumovax 23 has been a mainstay of adult pneumococcal vaccination for decades. It covers 23 pneumococcal serotypes and reduces invasive pneumococcal disease (IPD) in adults with certain risk factors. The reason it’s being stepped back is about the biology of how it works.

Polysaccharide vaccines (like Pneumovax 23) produce a T-cell-independent immune response — the B cells produce antibodies without requiring T-cell help. This generates reasonable short-term protection but limited immunological memory. Immunity wanes. In older adults and immunocompromised patients — the populations who need protection most — polysaccharide vaccine responses are often weaker.

Conjugate vaccines link the polysaccharide antigen to a protein carrier. This recruits T-cell help, generates immunological memory, and produces a stronger, more durable response. The RACGP’s summary quotes Dr Rodney Pearce, Chair of the Immunisation Coalition: “With a 23 we’ve got lots of coverage, but not high-quality coverage that lasts for a long time.” Capvaxive provides high-quality coverage across its 21 serotypes.

Prevanar 20 (20vPCV) is already on the NIP for all Australian children. Capvaxive completes the adult side of that transition. The two vaccines together — conjugate across the full lifespan — are a more robust population immunisation strategy than polysaccharide vaccines in adults ever were.

The disease burden this is addressing

Invasive pneumococcal disease in Australia remains a significant cause of morbidity and mortality, particularly in older adults. In 2025, 2,638 IPD cases were recorded nationally — 37% in adults over 65, and 14% in children under 5. In the first half of 2026 alone, NCIRS data recorded 911 IPD cases nationally.

Non-invasive pneumococcal infections — sinusitis, otitis media — are far more common and often self-limiting, though significant in terms of healthcare burden and antibiotic use. IPD, by contrast, can affect the lungs, brain, spinal cord, and bloodstream, and can be life-threatening. The populations with the highest burden — older adults, Aboriginal and Torres Strait Islander communities, people with chronic conditions — are precisely the populations the expanded NIP eligibility now covers.

Who needs to act

The eligibility changes effective 1 July mean several groups should be actively offered Capvaxive:

Adults turning 65 (or already over 65) without a recent pneumococcal vaccine: Previously eligible at 70, these individuals can now access a free vaccine at their GP clinic or pharmacy. Dr Pearce notes that awareness has historically been poor: “To date, many Australians and even healthcare professionals have been unsure about who can be vaccinated against pneumococcal disease and when.” The new simplified schedule is an opportunity to address that gap.

Aboriginal and Torres Strait Islander adults aged 25 and over: The eligibility reduction from 50 to 25 reflects the higher burden of IPD in First Nations communities, the earlier onset of risk factors including chronic respiratory and metabolic conditions, and the importance of earlier protection in that clinical context. GPs practising in, or serving, First Nations communities should be actively offering vaccination at routine contacts.

Adults 18+ with chronic conditions: COPD, chronic liver disease, and other conditions included in the new eligibility criteria substantially increase IPD risk. These patients are often already known to their GP for the condition itself — pneumococcal vaccination is a natural addition to the preventive care plan at any review visit.

The practical implementation question

The RACGP article notes implementation inconsistencies: some clinics reported stock availability delays in July despite the 22 June notification to providers. If Capvaxive is not yet available at a particular clinic or pharmacy, Prevanar 20 is an alternative conjugate vaccine and is also NIP-funded for eligible adults. Your GP or pharmacist will know current local stock status.

Revaccination for those who had Pneumovax 23 previously is possible at 12+ months after the prior dose. Whether this is needed clinically depends on the individual’s history, underlying conditions, and time elapsed since prior vaccination.

---

My two cents

This is one of the cleaner preventive health wins in recent Australian immunisation policy: a more effective vaccine, a lower eligibility age, more people covered, and a clearer schedule that removes some of the historical confusion about who gets what and when.

The confusion point is worth dwelling on. Pneumococcal vaccination in adults has historically been poorly communicated — when to get it, which product, whether it’s free. Dr Pearce’s observation that healthcare professionals themselves have been unsure about eligibility is honest and reflects what clinical practice has actually looked like. The NIP listing, combined with the transition away from Pneumovax 23, simplifies the conversation: conjugate vaccine, free, starting at 65 for the general adult population, 25 for Aboriginal and Torres Strait Islander adults, 18 for those with qualifying conditions.

For a 45-year-old reading this: the new age thresholds don’t affect you yet unless you have a qualifying chronic condition or are an Aboriginal or Torres Strait Islander adult. But this is worth noting for parents or partners aged 65+, and worth asking your GP about if you live with COPD, chronic liver disease, or another condition that puts you in the newly eligible group.

Verdict: yes — significant NIP change, 1.8 million newly eligible Australians, clear clinical action.

---

Sources cited

1. New pneumococcal vaccine added to NIP. RACGP newsGP, 30 June 2026. https://www1.racgp.org.au/newsgp/clinical/new-pneumococcal-vaccine-added-to-nip
2. Australian Immunisation Handbook — pneumococcal disease. https://immunisationhandbook.health.gov.au/vaccines/pneumococcal
3. NCIRS — pneumococcal vaccines fact sheet. https://www.ncirs.org.au/vaccines/pneumococcal-vaccines